GlassScriptPhysician profile
Tyler D Lash
NPI 1437449949
$4,394.77
in general payments reported to CMS, 2019-2025
40 companies · $603 in 2025
The $603 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,074 · 2020: $253 · 2021: $375 · 2022: $131 · 2023: $450 · 2024: $510 · 2025: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,383 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,383.28 |
| Education | $179.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $701.87 | 2019-2024 | |
| Daiichi Sankyo INC. | $421.15 | 2019-2025 | Enhertu, Injectafer |
| Pfizer INC. | $335.17 | 2019-2024 | |
| Abbvie INC. | $277.85 | 2024-2025 | |
| Janssen Biotech, INC. | $274.34 | 2019-2023 | Darzalex, Tecvayli |
| Merck Sharp & Dohme LLC | $252.06 | 2019-2024 | Keytruda |
| Tempus Ai, INC | $203.44 | 2024-2025 | Xt Cdx |
| E.R. Squibb & Sons, L.L.C. | $184.98 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $166.91 | 2019-2024 | Imfinzi |
| Dendreon Pharmaceuticals LLC | $165.81 | 2021-2025 | Provenge |
| Genzyme Corporation | $148.72 | 2019-2024 | |
| Astellas Pharma US INC | $131.62 | 2019-2025 | |
| Bard Peripheral Vascular, INC. | $125.00 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $112.81 | 2019-2021 | |
| Genentech USA, INC. | $91.39 | 2019-2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Lash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.